Bioavailability of ketoprofen in man with and without concomitant administration of aluminium phosphate.
The purpose of this study was to determine whether a concomitant single dose of antacid (aluminium phosphate), or multiple doses of this antacid, administered prior to and with ketoprofen would alter the bioavailability of this non steroidal anti-inflammatory agent. The possible effects of aluminium phosphate were evaluated following administration of ketoprofen alone (Phase I), co-administration of antacid and ketoprofen (Phase II), and antacid for four days before administration of ketoprofen with co-administration on the day of the study (Phase III). There were no significant differences between treatment means for peak plasma concentration, time to peak plasma concentration, and area under the plasma concentration-time curve. The observed differences were due only to individual effects. The results indicate a lack of interaction between ketoprofen and the antacid aluminium phosphate (Phosphalugel).
D017607:Aluminum Compounds; D000863:Antacids / Q000008:administration & dosage* / Q000494:pharmacology; D001682:Biological Availability; D004347:Drug Interactions; D006801:Humans; D007660:Ketoprofen / Q000008:administration & dosage / Q000378:metabolism*; D010666:Phenylpropionates / Q000378:metabolism*; D010710:Phosphates / Q000008:administration & dosage*
D017607:Aluminum Compounds; D000863:Antacids; D010666:Phenylpropionates; D010710:Phosphates; D007660:Ketoprofen; C012714:aluminum phosphate